Testing KST-6051 in advanced cancers with a KRAS mutation
Tests the safety of KST-6051 in adults with KRAS-mutant advanced solid tumors.
Plain-language title generated from the registry record
Registry title: A Phase 1 Dose Escalation and Dose Expansion Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
Key facts
- Where
- Boston, Fairfax, Houston, Los Angeles, Philadelphia, Salt Lake City, San Antonio, Sarasota, and Tampa, United StatesSee the 9 sites
- Phase
- Phase 1
Where in United States
- Mass General Brigham Cancer Institute at Massachusetts General HospitalBoston, United StatesTaking people
- NEXT VirginiaFairfax, United StatesTaking people
- The University of Texas MD Anderson Cancer CenterHouston, United StatesTaking people
- Cedars-Sinai Medical CenterLos Angeles, United StatesTaking people
- Sidney Kimmel Cancer CenterPhiladelphia, United StatesTaking people
- Huntsman Cancer Institute/University of UtahSalt Lake City, United StatesTaking people
- NEXT OncologySan Antonio, United StatesTaking people
- Florida Cancer SpecialistsSarasota, United StatesTaking people
- Moffitt Cancer CenterTampa, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Kestrel Therapeutics, Inc.
- Trial code
- NCT07458347
- Record updated
- 15 October 2026
- Original description
The main purpose of the trial is to assess whether the trial drug, KST-6051, is safe and tolerable when administered orally, alone or in combination with other anticancer agents, to adults with advanced or metastatic solid tumors with certain KRAS mutations.Read full original descriptionShow less
A First-in-human Phase 1 Dose Escalation and Dose Expansion Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of KST-6051 in Patients With Advanced or Metastatic Solid Tumors With a KRAS Mutation
The main purpose of the trial is to assess whether the trial drug, KST-6051, is safe and tolerable when administered orally, alone or in combination with other anticancer agents, to adults with advanced or metastatic solid tumors with certain KRAS mutations.
Inclusion: Age ≥ 18 years; Willing and able to give written informed consent; Histologically documented locally advanced and unresectable or metastatic NSCLC, PDAC, CRC, or other solid tumor; Documentation of KRAS mutation prior to the first dose of trial drug(s); Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1; Adequate cardiovascular, hematological, liver, and renal function; Measurable disease at baseline per Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST 1.1).
Exclusion: Inability to swallow oral medications; Central nervous system (CNS) tumors or untreated or unstable metastases; Pregnant, breastfeeding, or expecting to conceive or father children within the projected duration of the trial; Other inclusion/exclusion criteria are specified in the protocol.